Factor VII Padua in Iran: A Study on 150 Patients With Factor VII Deficiency
- 27 May 2025
- journal article
- Published by Wiley in Haemophilia
- Vol. 31 (4) , 771-779
Abstract
Introduction: Factor (F) VII Padua is an ultra‐rare type II FVII deficiency characterized by discrepancies in FVII activity across different thromboplastin types. Due to the high prevalence of consanguineous marriages in Iran, rare bleeding disorders, including FVII deficiency, are more common. Accurate identification of FVII Padua is critical to avoid inappropriate treatments and thrombotic risks. Aim: This study aimed to determine the incidence and clinical and laboratory characteristics of FVII Padua among Iranian patients with FVII deficiency. Method: One hundred fifty Iranian patients aged 18 years or older with confirmed FVII deficiency were included. PT testing was performed using rabbit brain, human placenta and recombinant human thromboplastins. Patients with PT discrepancies consistent with FVII Padua underwent genetic analysis of F7 exon 9 for the Arg364Gln mutation. Results: Thirteen patients (8.6%) exhibited PT patterns indicative of FVII Padua. HRM analysis identified nine heterozygous and two homozygous cases for the Padua variant; subsequently, sequencing analysis confirmed the Arg364Gln variant in two patients. Sequencing also revealed four additional variants in exon 9. The confirmed Padua cases presented diverse manifestations, ranging from asymptomatic to symptomatic, including bruising, epistaxis, gastrointestinal bleeding and gum bleeding. Conclusion: FVII Padua is relatively prevalent among Iranian patients with FVII deficiency . Molecular testing is essential for accurate diagnosis, enabling appropriate management and preventing unnecessary interventions. Tailored diagnostic strategies are crucial in regions with high consanguinity rates to optimize patient care and reduce thrombotic risks.Keywords
Funding Information
- Iran University of Medical Sciences (27175)
This publication has 34 references indexed in Scilit:
- Molecular basis of rare congenital bleeding disordersBlood Reviews, 2022
- The EAHAD blood coagulation factor VII variant databaseHuman Mutation, 2020
- Congenital FVII deficiency and thrombotic events after replacement therapyJournal of Thrombosis and Thrombolysis, 2011
- Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIaJAMA, 2006
- Kinetics of Human Factor VII ActivationBiochemistry, 1996
- Impaired human tissue factor-mediated activity in blood clotting factor VIINagoya (Arg304–>Trp). Evidence that a region in the catalytic domain of factor VII is important for the association with tissue factor.Journal of Biological Chemistry, 1994
- Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism.Journal of Biological Chemistry, 1993
- Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7)Human Genetics, 1992
- The coagulation cascade: initiation, maintenance, and regulationBiochemistry, 1991
- Purification and properties of human coagulation factor VII.Journal of Biological Chemistry, 1980